The non-obese diabetic (NOD) mouse as a model of human type 1 diabetes

Methods in Molecular Biology

Volumn 933, Issue , 2012, Pages 3-16

  Kachapati, Kritika ^a   Adams, David ^a   Bednar, Kyle ^a   Ridgway, William M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmune; CD137; CTLA4; Insulin dependent diabetes loci (idd); MHC genes; NOD mouse; Prevention of diabetes; Quantitative trait loci; Type 1 diabetes

Indexed keywords

CD137 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE MODEL; GENETIC VARIABILITY; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL;

EID: 84934440038     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-68-7_1     Document Type: Article

References (71)

1. Driver JP, Serreze DV, Chen YG (2011) Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol 33:67-87
2. Thayer TC, Wilson SB, Mathews CE (2010) Use of nonobese diabetic mice to understand human type 1 diabetes. Endocrinol Metab Clin North Am 39:541-561
3. Wicker LS, Clark J, Fraser HI, Garner VE, Gonzalez-Munoz A, Healy B, Howlett S, Hunter K, Rainbow D, Rosa RL, Smink LJ, Todd JA, Peterson LB (2005) Type 1 diabetes genes and pathways shared by humans and NOD mice. J Autoimmun 25(Suppl):29-33
4. Ridgway WM, Peterson LB, Todd JA, Rainbow DB, Healy B, Burren OS, Wicker LS (2008) Gene-gene interactions in the NOD mouse model of type 1 diabetes. Adv Immunol 100:151-175
5. Culina S, Boitard C, Mallone R (2011) Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks? Clin Dev Immunol 2011:286248
6. Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464: 1293-1300
7. Oikawa Y, Shimada A, Yamada Y, Okubo Y, Katsuki T, Shigihara T, Miyazaki J, Narumi S, Itoh H (2010) CXC chemokine ligand 10 DNA vaccination plus Complete Freunds Adjuvant reverses hyperglycemia in non-obese diabetic mice. Rev Diabet Stud 7:209-224
8. Tarbell KV, Petit L, Zuo X, Toy P, Luo X, Mqadmi A, Yang H, Suthanthiran M, Mojsov S, Steinman RM (2007) Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L + regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 204:191-201
9. Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH (2008) Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes 57:3013-3024
10. Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, Battaglia M, Gregori S, Mathews CE, Song S, Troutt M, Eisenbeis S, Williams J, Schatz DA, Haller MJ, Atkinson MA (2009) Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 58:2277-2284
11. Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS, Shlomchik MJ, Wen L (2007) Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 117:3857-3867
12. Nikolic B, Takeuchi Y, Leykin I, Fudaba Y, Smith RN, Sykes M (2004) Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes 53:376-383
13. Jurewicz M, Yang S, Augello A, Godwin JG, Moore RF, Azzi J, Fiorina P, Atkinson M, Sayegh MH, Abdi R (2010) Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 59: 3139-3147
14. Tian L, Gao J, Hao J, Zhang Y, Yi H, OBrien TD, Sorenson R, Luo J, Guo Z (2010) Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 151: 3049-3060
15. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A (2008) Combination therapy with glucagon-like peptide- 1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281-3288
16. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, Chatenoud L, Klatzmann D, Salomon BL, Piaggio E (2010) IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 207:1871-1878
17. Koulmanda M, Bhasin M, Hoffman L, Fan Z, Qipo A, Shi H, Bonner-Weir S, Putheti P, Degauque N, Libermann TA, Auchincloss H Jr, Flier JS, Strom TB (2008) Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A 105:16242-16247
18. Bresson D, Fradkin M, Manenkova Y, Rottembourg D, von Herrath M (2010) Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/ GAD65 combination therapy in new-onset type 1 diabetes. Mol Ther 18:307-316
19. Godebu E, Summers-Torres D, Lin MM, Baaten BJ, Bradley LM (2008) Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells. J Immunol 181:1798-1805
20. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA (2008) Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 105:18895-18900
21. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D (1999) Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 189:331-339
22. Rosmalen JG, Leenen PJ, Katz JD, Voerman JS, Drexhage HA (1997) Dendritic cells in the autoimmune insulitis in NOD mouse models of diabetes. Adv Exp Med Biol 417:291-294
23. Saxena V, Ondr JK, Magnusen AF, Munn DH, Katz JD (2007) The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J Immunol 179:5041-5053
24. Wong FS, Janeway CA Jr (1997) The role of CD4 and CD8 T cells in type I diabetes in the NOD mouse. Res Immunol 148:327-332
25. Ziegler AG, Nepom GT (2010) Prediction and pathogenesis in type 1 diabetes. Immunity 32:468-478
26. Mueller DL (2003) Tuning the immune system: competing positive and negative feedback loops. Nat Immunol 4:210-211
27. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT (2005) A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23:115-126
28. Roep BO, Atkinson M, von Herrath M (2004) Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 4:989-997
29. Atkinson MA, Leiter EH (1999) The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 5:601-604
30. Wicker LS, Todd JA, Peterson LB (1995) Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 13:179-200
31. Wicker LS, Miller BJ, Coker LZ, McNally SE, Scott S, Mullen Y, Appel MC (1987) Genetic control of diabetes and insulitis in the nonobese diabetic (NOD) mouse. J Exp Med 165:1639-1654
32. Todd JA, Aitman TJ, Cornall RJ, Ghosh S, Hall JR, Hearne CM, Knight AM, Love JM, McAleer MA, Prins JB et al (1991) Genetic analysis of autoimmune type 1 diabetes mellitus in mice. Nature 351:542-547
33. Burren OS, Adlem EC, Achuthan P, Christensen M, Coulson RM, Todd JA (2011) T1DBase: update 2011, organization and presentation of large-scale data sets for type 1 diabetes research. Nucleic Acids Res 39:D997-D1001
34. Ridgway WM, Healy B, Smink LJ, Rainbow D, Wicker LS (2007) New tools for defining the genetic background of inbred mouse strains. Nat Immunol 8:669-673
35. Lyons PA, Hancock WW, Denny P, Lord CJ, Hill NJ, Armitage N, Siegmund T, Todd JA, Phillips MS, Hess JF, Chen SL, Fischer PA, Peterson LB, Wicker LS (2000) The NOD Idd9 genetic interval in fluences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. Immunity 13:107-115
36. Cannons JL, Chamberlain G, Howson J, Smink LJ, Todd JA, Peterson LB, Wicker LS, Watts TH (2005) Genetic and functional association of the immune signaling molecule 4-1BB (CD137/TNFRSF9) with type 1 diabetes. J Autoimmun 25(1):13-20
37. Podolin PL, Wilusz MB, Cubbon RM, Pajvani U, Lord CJ, Todd JA, Peterson LB, Wicker LS, Lyons PA (2000) Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene? Cytokine 12: 477-482
38. Kamanaka M, Rainbow D, Schuster-Gossler K, Eynon EE, Chervonsky AV, Wicker LS, Flavell RA (2009) Amino acid polymorphisms altering the glycosylation of IL-2 do not protect from type 1 diabetes in the NOD mouse. Proc Natl Acad Sci U S A 106:11236-11240
39. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE, Gonzalez-Munoz A, Clark J, Veijola R, Cubbon R, Chen SL, Rosa R, Cumiskey AM, Serreze DV, Gregory S, Rogers J, Lyons PA, Healy B, Smink LJ, Todd JA, Peterson LB, Wicker LS, Santamaria P (2007) Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 39:329-337
40. Rainbow DB, Esposito L, Howlett SK, Hunter KM, Todd JA, Peterson LB, Wicker LS (2008) Commonality in the genetic control of Type 1 diabetes in humans and NOD mice: variants of genes in the IL-2 pathway are associated with autoimmune diabetes in both species. Biochem Soc Trans 36:312-315
41. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511
42. Gerold KD, Zheng P, Rainbow DB, Zernecke A, Wicker LS, Kissler S (2011) The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. Diabetes 60:1955-1963
43. Wicker LS, Chamberlain G, Hunter K, Rainbow D, Howlett S, Tiffen P, Clark J, Gonzalez- Munoz A, Cumiskey AM, Rosa RL, Howson JM, Smink LJ, Kingsnorth A, Lyons PA, Gregory S, Rogers J, Todd JA, Peterson LB (2004) Fine mapping, gene content, comparative sequencing, and expression analyses support Ctla4 and Nramp1 as candidates for Idd5.1 and Idd5.2 in the nonobese diabetic mouse. J Immunol 173:164-173
44. Vijayakrishnan L, Slavik JM, Illes Z, Greenwald RJ, Rainbow D, Greve B, Peterson LB, Hafler DA, Freeman GJ, Sharpe AH, Wicker LS, Kuchroo VK (2004) An autoimmune diseaseassociated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 20:563-575
45. Irie J, Wu Y, Kachapati K, Mittler RS, Ridgway WM (2007) Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes. Diabetes 56:186-196
46. Maier LM, Smyth DJ, Vella A, Payne F, Cooper JD, Pask R, Lowe C, Hulme J, Smink LJ, Fraser H, Moule C, Hunter KM, Chamberlain G, Walker N, Nutland S, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Strachan DP, Peterson LB, Todd JA, Wicker LS, Twells RC (2005) Construction and analysis of tag single nucleotide polymorphism maps for six human-mouse orthologous candidate genes in type 1 diabetes. BMC Genet 6:9
47. Fung EY, Smyth DJ, Howson JM, Cooper JD, Walker NM, Stevens H, Wicker LS, Todd JA (2009) Analysis of 17 autoimmune diseaseassociated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun 10:188-191
48. Li L, Soetandyo N, Wang Q, Ye Y (2009) The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim Biophys Acta 1793:346-353
49. Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23:23-68
50. Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS (1993) Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 150:771-781
51. Vinay DS, Kwon BS (1998) Role of 4-1BB in immune responses. Semin Immunol 10:481-489
52. Croft M (2003) Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev 14:265-273
53. Croft M (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3:609-620
54. Foell J, McCausland M, Burch J, Corriazzi N, Yan XJ, Suwyn C, ONeil SP, Hoffmann MK, Mittler RS (2003) CD137-mediated T cell costimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice. Ann N Y Acad Sci 987:230-235
55. Fukushima A, Yamaguchi T, Ishida W, Fukata K, Mittler RS, Yagita H, Ueno H (2005) Engagement of 4-1BB inhibits the development of experimental allergic conjunctivitis in mice. J Immunol 175:4897-4903
56. Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, Fu YX (2002) Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 168: 1457-1465
57. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, MacIsaac KD, Levine SS, Fraenkel E, von Boehmer H, Young RA (2007) Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445:931-935
58. Chen Z, Herman AE, Matos M, Mathis D, Benoist C (2005) Where CD4 + CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med 202:1387-1397
59. Bertram EM, Lau P, Watts TH (2002) Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand in fluences T cell numbers late in the primary response and regulates the size of the T cell memory response following in fluenza infection. J Immunol 168:3777-3785
60. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS (2002) 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and B fl -1. J Immunol 169:4882-4888
61. Kim J, Choi SP, La S, Seo JS, Kim KK, Nam SH, Kwon B (2003) Constitutive expression of 4-1BB on T cells enhances CD4+ T cell responses. Exp Mol Med 35:509-517
62. Setareh M, Schwarz H, Lotz M (1995) A mRNA variant encoding a soluble form of 4-1BB, a member of the murine NGF/TNF receptor family. Gene 164:311-315
63. Schwarz H, Blanco FJ, von Kempis J, Valbracht J, Lotz M (1996) ILA, a member of the human nerve growth factor/tumor necrosis factor receptor family, regulates T-lymphocyte proliferation and survival. Blood 87:2839-2845
64. Shao Z, Sun F, Koh DR, Schwarz H (2008) Characterisation of soluble murine CD137 and its association with systemic lupus. Mol Immunol 45:3990-3999
65. Michel J, Schwarz H (2000) Expression of soluble CD137 correlates with activation-induced cell death of lymphocytes. Cytokine 12:742-746
66. Middendorp S, Xiao Y, Song JY, Peperzak V, Krijger PH, Jacobs H, Borst J (2009) Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma. Blood 114:2280-2289
67. Lennon GP, Bettini M, Burton AR, Vincent E, Arnold PY, Santamaria P, Vignali DA (2009) T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity 31:643-653
68. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, Vignali DA (2004) Correction of multi-gene deficiency in vivo using a single self-cleaving 2A peptide-based retroviral vector. Nat Biotechnol 22:589-594
69. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM (1998) Development of a self-inactivating lentivirus vector. J Virol 72:8150-8157
70. Weber K, Bartsch U, Stocking C, Fehse B (2008) A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol Ther 16:698-706
71. Follenzi A, Santambrogio L, Annoni A (2007) Immune responses to lentiviral vectors. Curr Gene Ther 7:306-315